In a development that might silence the critics of the Union government for allowing the emergency use of the COVID-19 jab developed by Bharat Biotech sans the phase 3 trial, the company on Wednesday announced that the vaccine has been found to be 81 per cent effective in phase 3 clinical trials. The efficacy percentage...

Prime Minister Narendra Modi on Monday received the first dose of the COVID-19 vaccine at All India Institute of Medical Sciences, New Delhi.  Notably, vaccination of senior citizens, as well as middle-aged people with comorbidities, has started from today. PM Modi took to Twitter to reveal the same. He said, “Took my first dose of...

Prime Minister Narendra Modi will launch the countrywide COVID-19 vaccination programme that is all set to begin on Saturday. Around 3 lakh healthcare workers are likely to receive the shot on day 1 of the vaccination drive. The vaccination campaign will start from 3,000 sites across the country on Saturday and 100 people will be...

After Serum Institute’s Covishield, the first batches of Bharat Biotech’s COVID-19 vaccine ‘Covaxin’ was despatched to 11 cities from Hyderabad on Wednesday. The vaccine stock has been sent to cities such as New Delhi, Chennai, Bengaluru, Lucknow, Patna and Jaipur. The development comes ahead of the initiation of vaccination against COVID-19 in the country scheduled...

Within hours of the Indian drug regulator clearing the COVID-19 vaccine of Bharat Biotech that is yet to complete the phase 3 clinical trial, Congress on Sunday hit out at the Centre for clearing the vaccine. In fact, not just Congress leaders, but Samajwadi Party president Akhilesh Yadav too questioned the hasty clearance of the...

In a major development, the Drugs Controller General of India (DCGI) on Sunday granted “restricted emergency use” authorisation to the vaccines being manufactured by Serum Institute of India (SII) and Bharat Biotech. The move comes at a time when COVID-19 cases in the country have already crossed 1.03 crore and the death toll is nearing...

Bharat Biotech, which is developing a vaccine against coronavirus—‘COVAXIN’—with the help of Indian Council of Medical Research (ICMR), is hopeful of launching the vaccine as early as February. The company, which will start the third-phase trials of the vaccine in November, has earlier predicted that COVAXIN will be available only in the second quarter. A...

Ahmedabad-based Zydus Cadila Healthcare Limited has got the nod from the Drugs Controller General of India (DCGI) for human clinical trials of its vaccine candidate developed for COVID-19. It is the second indigenous vaccine candidate to get permission for clinical trials. Earlier, Hyderabad-based Bharat Biotech had got the nod for clinical trial of its vaccine...

Aiming to launch an indigenous COVID-19 vaccine by August 15, the Indian Council of Medical Research has written to select medical institutions and hospitals to fast-track clinical trial approvals for the vaccine candidate Covaxin being developed in collaboration with Bharat Biotech. Twelve clinical trial sites have been identified at present and the apex health research...

The country’s ‘first’ indigenous COVID-19 vaccine COVAXIN, developed by Bharat Biotech in collaboration with ICMR and NIV, has got the nod for human clinical trials from the Drug Controller General of India, the company said. The Phase I and Phase II clinical trials of the vaccine for SARS-CoV-2, approved after pre-clinical studies demonstrated safety and...